Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25219229 | 0.89 | CYP1A2 (0.83) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL1812415 | 0.86 | CYP2C19 (0.57) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL1812414 | 0.86 | CYP1A2 (0.57) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL27582896 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL6847258 | 0.85 | CYP2C19 (0.68) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL27600244 | 0.84 | RECQL (0.91) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL6847172 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL25522729 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL5663865 | 0.83 | RECQL (0.89) | CYP1A2CYP2C19RECQLTSHRHTT | |
| SCHEMBL5718940 | 0.83 | USP2 (0.72) | CYP1A2CYP2C19RECQLHTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-110573509-A | MLKL inhibitors | 北京生命科学研究所 | 2019-12-13 | — | — | CN | disclosed |
| US-8470805-B2 | Processes for preparing piperazinium salts of KMUP and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | disclosed |
| WO-2012031445-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (CN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-06-09 | — | — | US | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
| US-4456605-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-06-26 | — | — | US | disclosed |
| US-4402957-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-09-06 | — | — | US | disclosed |
| US-4287195-A | USEFUL AS BACTERICIDES AND FUNGICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-09-01 | — | — | US | disclosed |
| EP-0007696-A1 | Heterocyclic derivatives of (4-(piperazin-1-yl-phenyloxymethyl)-1.3.-dioxolan-2-ylmethyl)-1H-imidazoles and -1H-1.2.4-triazoles, their preparation and use as fungicides and bactericides | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | U2SURP, RRP15, KYNU | CYP1A2 302/4885CYP2C19 1369/4885RECQL 2621/4885 |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | TK1, XDH, KYAT1 | CYP1A2 769/4885CYP2C19 2772/4885RECQL 3896/4885 |
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | CYP1A2 4629/4885CYP2C19 3887/4885RECQL 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.